Guest Post: Colorcon A Case Study – Part 1

May 7, 2017

Impact of Moisture Barrier Film Coating on Stability of Amoxicillin/Clavulanic Acid Tablets

Product stability is affected by all elements of solid dosage development and manufacturing including core formulation, excipient choice, manufacturing conditions, packaging and end use storage conditions. Film coating can protect tablets from environmental factors such as moisture, light, or oxygen while presenting the opportunity to improve product identification and patient compliance.

Impact of Moisture Barrier Film Coating on Stability of Amoxicillin/Clavulanic Acid Tablets

Amoxicillin and clavulanic acid are combined to produce an antibiotic with an increased spectrum of action against some amoxicillin-resistant bacteria. Due to the high sensitivity of clavulanic acid to moisture, this combination was selected to investigate the moisture protection properties of Opadry amb II. This antibiotic combination product is typically coated with an hypromellose (HPMC) based film coating.

Part I: In-Use Product Integrity

The in-use stability of an uncoated amoxicillin / clavulanic acid dosage form was compared against similar tablets coated using a standard HPMC- based film coating and Opadry amb II aqueous moisture barrier coating.
Uncoated and coated tablets were removed from their primary packaging and transferred to a typical consumer-use tablet organizer and stored for the prescribed ten-day regimen at 25°C/60% RH. On each day, tablets were removed from the organizer and assayed according to the USP method for each drug component.
Results showed significant degradation of the clavulanic acid for uncoated and HPMC-coated tablets. At the end of the ten-day dose regimen, amoxicillin levels were shown to have decreased by 20% of the initial amount, but still within the USP assay specification of 90-120%. In contrast, clavulanic acid levels were totally depleted at the end of ten days; however, tablets coated with Opadry amb II maintained acceptable levels.

Application of the Opadry amb II coating resulted in improved tablet stability, even when removed from the primary packaging.

Colorcon, from Core to Coating, Your Supplier of Choice

At Colorcon, we formulate, we innovate — and we focus our coatings and excipients exclusively for pharmaceutical and nutritional oral solid dosages.
That’s why, when you set out to select the right coating or excipient for your formulation, be sure to partner with the leading company that brings you innovative products plus specialized technical support when and where you need it.

Be confident with your choice

Author: Colorcon
Website: www.colorcon.com


Read More

Vitex to Expand Into the Aerotropolis
Read More >
Vitex CEO Dr Aniss Chami Appointed Board Director of CHP Australia
Read More >
Vitex Pharmaceuticals’ Chief Executive Officer, Dr Aniss Chami, a panel discussion with Blacktown City Council.
Vitex CEO Dr Aniss Chami Joins A Panel Discussion with Blacktown City Council
Read More >
Vitex Pharmaceuticals’ Chief Procurement Officer, Lucie Chami, discusses the impact of Coronavirus on procurement via Podcast on Chartered Institute of Procurement and Supply
Vitex CPO Lucie Chami Discusses the Impact of Coronavirus
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami shared the Vitex journey at the Advanced Manufacturing Symposium hosted by Blacktown City Council, on Thursday 24 October 2019 at Sydney Motorsport Park, Eastern Creek.
Vitex CEO Dr Aniss Chami Shares the Vitex Journey at the Advanced Manufacturing Symposium
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami delivered the keynote speech at the 16th edition of the World Forum for Foreign Direct Investment (FDI) 2019 held on Wednesday 19 June 2019 in Sydney, Australia.
Vitex CEO Dr Aniss Chami Delivers Keynote Speech at the 2019 World Forum for Foreign Direct Investment
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami joined the Western City & Aerotropolis Authority Industry Symposium that took place on Monday 16 December 2019 at Warwick Farm.
Vitex CEO Dr Aniss Chami Participates at the Western City & Aerotropolis Authority Industry Symposium
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami had the pleasure of hosting over forty foreign diplomats based in NSW. The Western Sydney Investment Attraction Office, on behalf of the Department of Foreign Affairs and Trade, organised a visit to Western Sydney to showcase investment and trade opportunities in this rapidly expanding region.
Vitex CEO Dr Aniss Chami Welcomes NSW Diplomats at Vitex Pharmaceuticals
Read More >
Vitex Pharmaceuticals’ CEO, Dr Aniss Chami delivered the keynote speech at the Inaugural International Foreign Direct Investment (FDI) Summit held on Tuesday 29 October 2019 in Huzhou, China.
Vitex CEO Dr Aniss Chami Delivers Keynote Speech at the International FDI Summit in Huzhou, China
Read More >